Wednesday, May 15, 2013

Saul Levin, M.D., Will Be Next APA Medical Director/CEO

The APA Board of Trustees announced today that it has chosen Saul Levin, M.D., M.P.A., to be the Association's next medical director/CEO. Levin will replace James H. Scully Jr., M.D., who will step down when his contract is up later this year. Scully has served in that post for the last 12 years. Levin has served on several APA components including the Board of APA's political action committee (APAPAC), the Scientific Program Committee, and as a consultant to the Finance and Budget Committee. He has also been a member of the APA delegation to the AMA.

Levin currently is the interim director of the District of Columbia Department of Health and chair of the D.C. Essential Health Benefits Package Subcommitee of the Health Benefit Exchange Authority. He has also served as senior deputy director of the District of Columbia Addiction and Recovery Administration. Before taking on his positions in Washington, D.C., Levin was vice president for science, medicine, and public health at the AMA.

Commenting on Levin's selection as medical director, APA President-elect Jeffrey Lieberman, M.D., said, "Saul’s expertise in electronic health information exchanges and implementation of the Affordable Care Act and meaningful-use requirements, as well as his commitment to mental health parity and proven leadership of large organizations, will be extremely important to APA and its members as we adapt to and continue our leadership role in health care reform.” Scully commented that Levin "brings extraordinary intelligence, vision, and great energy to the challenges ahead for our profession. I look forward to working together with him as we transition to the news leadership." Levin will become CEO-designate in mid-July and will become medical director and CEO when Scully retires in the fall.


The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.